AttendMe Owl Logo
AttendMe
Evidence Evolution
HematologyHematology

How This Evidence Evolved

CML Targeted Therapy

Imatinib, next-generation TKIs, and the prospect of curing CML

10.5

Timeline

Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

CML was once fatal within a few years; TKI treatment has changed that outlook. BCR-ABL is a constitutively activated tyrosine kinase that causes CML, providing a specific therapeutic target. In the 2001 phase 1 study, oral STI571 was given to 83 patients with chronic-phase CML after interferon alfa failure. Complete hematologic responses occurred in 53 of 54 patients receiving at least 300 mg daily, usually within four weeks. Cytogenetic responses occurred in 29 of those 54 patients, including seven complete cytogenetic remissions. These results demonstrated substantial activity from targeting BCR-ABL.
Proof

Landmark RCTs and pivotal trials that established the evidence base

IRIS randomized 1,106 patients with newly diagnosed chronic-phase CML to imatinib or interferon alfa plus low-dose cytarabine. At 18 months, estimated complete cytogenetic response was 76.2% with imatinib versus 14.5% with combination therapy. Freedom from progression to accelerated phase or blast crisis was 96.7% versus 91.5%. Imatinib was better tolerated. These findings established efficacy in first-line treatment; this report did not provide 8-year survival outcomes.
Extension

Follow-up studies, subgroup analyses, and real-world validation

ENESTnd and DASISION found deeper or faster responses with nilotinib and dasatinib than imatinib. STIM tested stopping imatinib after sustained complete molecular remission; persistent complete molecular remission at 12 months was 41% among 69 patients with ≥12-month follow-up. Among 755 evaluable EURO-SKI patients, molecular relapse-free survival was 50% at 24 months after stopping. ASCEMBL addressed later-line treatment: major molecular response at week 24 was 25.5% with asciminib versus 13.2% with bosutinib after at least two prior TKIs.
Guidelines

Integration into clinical practice guidelines and recommendations

ELN 2020 lists imatinib, dasatinib, nilotinib and bosutinib as first-line TKIs, with selection informed by ELTS risk, comorbidities and toxicity. qPCR is required at least every three months; milestones at 3, 6 and 12 months guide treatment. Discontinuation requires first chronic phase, reliable rapid molecular monitoring and agreement to frequent follow-up. Minimal criteria include typical transcripts, no prior failure, first-line therapy or second-line for intolerance, TKI exposure over five years (over four for second-generation TKIs), and MR4 or deeper for more than two years. Optimal criteria require longer MR4 duration. ELN 2025 provides updated first-line, sequencing and discontinuation guidance.
ELN Recommendations for Management of CML

Select first-line TKI by patient risk and comorbidities. Response milestones at 3, 6, and 12 months guide continuation or change. TFR requires sustained DMR and eligibility assessment; after stopping, monitor monthly for 6 months, every 2 months for months 6–12, then every 3 months.

European LeukemiaNet recommendations for the management of CML

Adult chronic-phase first-line: imatinib, dasatinib, nilotinib or bosutinib; asciminib where approved, radotinib in South Korea. After second-line resistance, asciminib or ponatinib if mutations/comorbidities permit; either for T315I. TFR: full eligibility and molecular monitoring.

Now

Current standard of care and ongoing research directions

ELN 2020 reports normal life expectancy for most patients with chronic-phase CML and identifies treatment-free remission as a goal. It lists four broadly available first-line TKIs and describes generic imatinib as a cost-effective initial treatment. After stopping nilotinib or dasatinib in selected patients, about half maintained treatment-free remission. More than 80% of molecular recurrences occurred within six to eight months after stopping; about 90–95% regained their previous molecular response after restarting a TKI. The 2020 panel described ponatinib as active against T315I and asciminib as promising but requiring more information. These are the guideline’s historical assessments.

Landmark Trials in This Story

New England journal of medicine 2001Landmark

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Hematologic and cytogenetic response rates

New England journal of medicinePhase 1N=83
IRIS2003Landmark

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

Complete cytogenetic response rate at 18 months

New England journal of medicineRCTN=1,106
ENESTnd2010Landmark

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

Major molecular response at 12 months

New England journal of medicineRCTN=846
DASISION2010Landmark

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

Complete cytogenetic response at 12 months

New England journal of medicineRCTN=519
STIM2010Landmark

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

12-month persistent CMR: 41% (95% CI 29–52); 69 had ≥12-month follow-up.

Lancet OncolProspective CohortN=100
EURO-SKI2018

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Among 755 evaluable: molecular relapse-free survival 61% at 6 months, 50% at 24 months.

The Lancet. OncologyProspective nonrandomized discontinuation trialN=758
ASCEMBL2021

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.

Major molecular response at 24 weeks: asciminib 25.5% vs bosutinib 13.2% (adjusted difference 12.2%, 95% CI 2.19–22.30)

BloodRandomized open-label trialN=233

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

How did imatinib change the natural history of CML?+
Imatinib transformed CML treatment by improving cytogenetic response and reducing progression compared with interferon alfa plus cytarabine. The ELN recommendations state that most patients with chronic-phase CML now have normal life expectancy. Treatment-free remission is a further goal for selected patients with durable deep molecular response.
What is treatment-free remission in CML?+
Treatment-free remission means maintaining molecular response after stopping a TKI. ELN 2025 requires full eligibility and reliable molecular monitoring: every 6–8 weeks for 6 months, every 2 months during months 6–12, then every 3–6 months; test more often if transcripts rise. Restart if major molecular response is lost. STIM reported responses to imatinib reintroduction in all patients who relapsed.
When should second-generation TKIs be preferred over imatinib as first-line?+
Nilotinib and dasatinib produce faster or deeper responses than imatinib, but drug choice must consider comorbidities. ELN 2020 identifies arteriovascular disease as a strong contraindication to first-line nilotinib unless there is unique need, and respiratory failure or pleuropulmonary disease as strong contraindications to first-line dasatinib. Generic imatinib is a cost-effective initial option in chronic phase.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026